Hyperhemolysis syndrome: theory and practice
##plugins.themes.bootstrap3.article.main##
Abstract
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Aygun B., Padmanabhan S., Paley C., Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion. 2002, vol. 42, no.1, pp. 37–43. https://doi.org/10.1046/j.1537-2995.2002.00007.x
Babb A., Diamantos N., Sekhar M. Hyperhemolysis syndrome treated with corticosteroids and darbopoietin in patients with malte cell lymphoma. Transfus. Med., 2012, vol. 22, no.2, pp. 142–144. https://doi.org/10.1111/j.1365-3148.2011.01095.x
Bachmeyer C., Maury J., Parrot A. et al. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia. Am. J. Hematol., 2010, vol. 85, no.1, pp. 91–92. https://doi.org/10.1002/ajh.21578
Ballas S.K., Marclina M.J. Hyperhemolysis during the evolution of uncomplicated acute painful episodes in patients with sickle cell anemia. Transfusion, 2006. – vol. 46, no.1, pp. 105–110. https://doi.org/10.1111/j.1537-2995.2006.00679.x
Benson K., Agosti S.J., Latoni-Benedetti G.E. Acute and delayed hemolytic transfusion reactions secondary to HLA alloimmunization. Transfusion. – 2003, vol. 43, no.6, pp. 753–757. https://doi.org/10.1046/j.1537-2995.2003.00381.x
Chadebech P., Habibi A., Nzouakou R. et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: avidence of an emerging syndrome with suicidal red blood cell death. Transfusion, 2009, vol.49, no.9, p. 1785–1792. https://doi.org/10.1111/j.1537-2995.2009.02199.x
Darabi K., Dzik S. Hyperhaemolysis syndrome in anemia of chronic disease. Transfusion, 2005, vol.45, no. 12, pp. 1930–1933. https://doi.org/10.1111/j.1537-2995.2005.00608.x
Delmonte L., Cantini M., Olivieri O., De Franceschi L. Immunoglobulin resistant delayed hemolytic transfusion reaction treated with rituximab in an adult sickle cell patient. Transfusion, 2013, vol. 53, no.3, pp. 688–689. https://doi.org/10.1111/trf.12090
De Montalembert M., Dumont M.D., Heilbronner C. et al. Delayed hemolytic transfusion reaction in children with sickle disease. Hematologica, 2011, vol.96, no.6, pp. 801–807. https://doi.org/10.3324/haematol.2010.038307
El-Husseini A., Sabry A. Fatal hyperhemolytic delayed transfusion reaction in sickle cell disease: a case report and literature review. Am. J. Emerg. Med., 2010, vol. 28, no.9, pp. e5-8. https://doi.org/10.1016/j.ajem.2010.01.032
Garratty G. The James Blundell Award Lecture: do we really understand immune red cell destruction? Transfus. Med. 2008, vol. 18, no.6, pp. 321-334. https://doi.org/10.1111/j.1365-3148.2008.00891.x
Garratty G. What do we mean by «hyperhemolysis» and what is the cause? Trandfus.Med. – 2012. – vol.22, no.2, pp. 77–79. https://doi.org/10.1111/j.1365-3148.2012.01151.x
Grainger J.D., Makar Y., McManus A., Wynn R. Refractory hyperhaemolysis in a patient with beta-thalassaemia major. Transfus. Med. – 2001. – vol.11, no.1, pp. 55–57. https://doi.org/10.1046/j.1365-3148.2001.00278.x
Hannema S.E., Brand A., van Meurs A., Smiers F.G. Delayed hemolytic transfusion reaction with hyperhemolysis after first red cell transfusion in child with beta-thalassemia: challender in treatment. Transfusion, 2010, vol.50, no.2, pp. 429–432. https://doi.org/10.1111/j.1537-2995.2009.02399.x
Islam M.S., Chia L. Hyperhemolysis syndrome in a patient with sickle cell disease with erythrophagocytosis in peripheral blood. Eur. J. Haematol., 2010, vol.84, no.2, p. 188. https://doi.org/10.1111/j.1600-0609.2009.01351.x
McGlennan A.P., Grundy E.M. Delayed hemolytic transfusion reaction and hyperhemolysis complicating peri-operative blood transfusion in sickle cell disease. Anaesthesia, 2005, vol.60, no.6, pp. 609-612. https://doi.org/10.1111/j.1365-2044.2005.04188.x
McCullough J. (ed.) Transfusion medicine. – 4th ed., Wiley Blackwell, 2017. – 603 p.
Muro M., Palacios S., Moya-Quiles R. et al. Acute hemolytic transfusion reactions secondary to human leukocyte antigen alloimmunization. Int. J. Lab. Hematol., 2008, vol.30, no.1, pp. 84–86. https://doi.org/10.1111/j.1751-553X.2006.00889.x
Noizat-Pirenne F., Bachir D., Chadebech P. et al. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica. 2007, vol. 92, no.12, pp. e132–135. https://doi.org/10.3324/haematol.12074
Peltz L.D. Bystander immune cytolysis. Transfus. Med. Rev. 2006. – vol. 20, no.21, pp. 110–140. https://doi.org/10.1016/j.tmrv.2005.11.002
Ragimov A.A. (ed.) Transfusiologija: nazional’noe rukovodstvo. Moskva: GEOTAR-Media, 2012, 1184 p.
Rukavitsyn O.A. (ed.) Gematologija: nazional’noe rukovodstvo [Hematology: textbook]. Moskva: GEOTAR-Media, 2015, 776 p.
Scheunemann L.P., Ataga K.I. Delayed hemolytic transfusion reaction in sickle cell disease. Am. J. Med. Sci., 2010, vol.339, no.3, pp. 266–269. https://doi.org/10.1097/MAJ.0b013e3181c70e14
Shamov I.A., Bajgishieva N.Ch. Serpovidnokletochnaja bolezn’ [Sickle cell diseases]. – Mahachkala: izdatel’sko poligraficheskij zentr DGMA, 2006. – 160 p.
Sheiman B.S., Voloshina N.A., Safronova I.A., Urin A.A. Ostraja gemoliticheskaja anemija i ostroe povrezhdenije pochek (profilaktika i lechenije). Bil’, zneboluvannja і intensivnaja terapija, 2013, no.4, pp. 33–39.
Takeuchi C., Ohto H., Miura S. et al. Delayed and acute hemolytic transfusion reactions resulting from red cell antibodies and red cell-reactive HLA antibodies. Transfusion, 2005, vol. 45, no.12, pp. 1925–1929. https://doi.org/10.1111/j.1537-2995.2005.00607.x
Talano J.A., Hillery C.A., Guttshall J.L., Scott J.P. Delayed hemolytic transfusion reaction / hyperhemolysis syndrome in children with sickle disease. Pediatrics, 2003, vol.111, no.6, pt.1, e661–665.
Taylor J.G., Nolan V.G., Mendelsohn L., Kato G.J., Gladwin M.T., Steinberg M.H. Chronic hyperhemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PloS One. – 2008. – no. 2(5), e2095. https://dx.doi.org/10.1371%2Fjournal.pone.0002095
Volkova M. A. (2007) Сlinical oncohematology. A manual for the physician. Ed. by M.A. Volkova. 2nd edition, updated. Moskow: Meditsina Publichers. – 1120 p.
Win N. Hyperhemolysis syndrome in sickle cell disease. Expert Rev. Hematol. – 2009. – vol. 2, no. 2, pp. 111–115. https://doi.org/10.1586/ehm.09.2
Win N., Lee E., Needs M. et al. Measurement of macrophage marker in hyperhemolytic transfusion reaction: a case report. Transfus. Med. 2012, vol.22, no.2, pp. 137–141. https://doi.org/10.1111/j.1365-3148.2011.01131.x
Win N., New H., Lee E., de la Fuente J. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review. Transfusion, 2008, vol. 48, no.6, pp. 1231–1238. https://doi.org/10.1111/j.1537-2995.2008.01693.x
Win N., Sincha S., Lee E., Mills W. Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review. Transfus. Med. Rev. 2010. – vol. 24, no.1, pp. 64–67. https://doi.org/10.1016/j.tmrv.2009.09.006
Wintrobe’s clinical hematology / [ed. by J.P. Greer, D.A. Arber, B. Glader et al.], 13th ed., Philadelphia: Lippincott Williams & Wilkins, 2014. – 2278 p.
Yazdanbakhsh K., Ware R.E., Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012, vol.120, no.3, pp. 528–537. https://doi.org/10.1182/blood-2011-11-327361
Zimring J.C., Spitalnik S.L. To RBC or not to RBC: the role of suicidal death in hemolytic transfusion reactions. Transfusion, 2009, vol.49, no.9, pp. 1776–1778. https://doi.org/10.1111/j.1537-2995.2009.02339.x